GET DAILY SIGNALSQuanterix (QTRX): Can the Stock Climb Back to the $4 Level?
Key Takeaways
- The $4.00 target reflects a widely discussed price objective from earlier analyst commentary and a round-number threshold, not a current consensus; the average of three live targets sits below the recent share price.
- With a recent close near $3.38, reaching $4.00 would require a rise of roughly 18%.
- Current analyst price targets range from $3.00 to $3.50, with the arithmetic mean at about $3.17.
- Supporting factors include a return to sequential revenue growth, a more-than-doubling of LucentAD test volumes, and new Florida Medicaid reimbursement.
- Key risks include continued cash burn, a narrowed full-year revenue outlook, and a less certain FDA timeline for LucentAD.
- For more detail on the ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages for each.
- Readers can also explore Trending AI Robots to see how artificial intelligence is being applied to signal generation across markets.
Analyst Price Targets and Consensus View
Quanterix does have analyst coverage, but it does not currently support a meaningful upside target. Three verified targets were reviewed: TD Cowen's Dan Brennan raised his target to $3.50 from $3.00 (Hold) on October 13, 2026, while Canaccord Genuity's Kyle Mikson cut his to $3.00 from $4.00 (Hold) in August 2026, with a third firm also at $3.00. That produces a range of $3.00 to $3.50 and a mean of roughly $3.17—which is below the stock's recent price of about $3.38. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Because no current analyst target sits at least 10% above the market price, the $4.00 figure used here is a fallback objective drawn from public discussion rather than a live analyst consensus. Notably, $4.00 was a level both TD Cowen (cutting from $7.00) and Canaccord Genuity cited earlier in 2026 before lowering their targets as the turnaround stalled. It also marks a round-number threshold between the current price and the stock's 52-week high. Investors should treat it as a widely referenced marker, not a prediction.
Current Market Position and Path Toward the Target
The shares closed near $3.38 in the session following the third-quarter report, up sharply from a prior close around $2.90. Reaching $4.00 implies about 18% of additional upside—a substantial move for a company still unprofitable on a GAAP basis. Third-quarter revenue of $35.0 million rose 6.3% sequentially but fell 13.1% year over year, while the net loss narrowed to $21.6 million. Full-year revenue guidance was narrowed to $142 million to $146 million, and management now targets roughly $70 million in year-end cash.
What Could Support a Move Toward the Target
The bull case rests on early signs of a commercial turnaround. Sequential growth returned, the Americas grew in the high teens, Accelerator Lab bookings posted a book-to-bill near 2x for a second straight quarter, and LucentAD test volumes more than doubled as new reference-lab partners came online. Reimbursement finalized at $480 per test with coverage retroactive to July 2026, and Florida Medicaid coverage began in November 2026. If diagnostics scale into 2027 as management expects, the revenue inflection could support a re-rating toward higher levels. From what I see, monitoring these volume trends closely will be key.
What Could Prevent the Target From Being Reached
The bear case is equally concrete. Cash burn of $16.2 million in the quarter forced repeated cuts to the year-end cash target, and cash-flow breakeven has slipped into 2027. Instrument placements and services revenue remain weak, diagnostics partner revenue fell, and management shifted its FDA language on LucentAD to "cannot predict" timing while rivals Roche and C2N are already cleared. Any further cash need, dilution, or competitive setback could keep the stock anchored well below $4.00.
Technical Levels and Market Structure
Quanterix's 52-week range runs from about $2.15 to $8.77, underscoring how far the stock has fallen from prior highs. The $3.00 area acted as a recent pivot, and the shares have now reclaimed that zone. The $4.00 level represents both a psychological round number and a former support/target zone that, if the stock advanced, would become the next notable resistance level for traders to watch. One thing that stands out is how the stock has behaved around these round numbers in the past.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though the three current targets cited above are too close to the price to imply meaningful upside. Investors should monitor fourth-quarter revenue against the roughly $40 million needed to hit guidance, LucentAD volume and reimbursement adoption, any clarity on the FDA timeline, cash balance and potential financing activity, and analyst target revisions, which have trended lower through 2026. I’m watching this closely as the next earnings cycle unfolds.
AI Daily Buy/Sell Signals
In my own research process, I frequently turn to Tickeron’s AI Daily Buy/Sell Signals to help track momentum in names like this. The system continuously monitors thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like Quanterix, these signals can help surface opportunities and spot shifting trends more efficiently.
Final Assessment
Can Quanterix reach $4.00? It is a plausible but unproven path. The $4.00 objective is a publicly discussed marker, not a current analyst consensus—indeed, the three live targets average only about $3.17, below the stock price. Getting to $4.00 requires roughly 18% more upside driven by sustained diagnostics scaling, reimbursement traction, and a genuine return to growth. Against that stand cash burn, a narrowing guidance range, and an uncertain FDA path. The next several quarters of LucentAD adoption and cash discipline will determine whether that threshold is realistic.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for QTRX turns positive, indicating new upward trend
QTRX saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 79 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for QTRX just turned positive on November 09, 2026. Looking at past instances where QTRX's MACD turned positive, the stock continued to rise in 38 of 48 cases over the following month. The odds of a continued upward trend are 79%.
QTRX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +22.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where QTRX advanced for three days, in 209 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 114 of 144 cases where QTRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for QTRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 24 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 53 cases where QTRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
The 10-day moving average for QTRX crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QTRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
QTRX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.577) is normal, around the industry mean (4.142). P/E Ratio (-1.105) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.894) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. QTRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of protein diagnostic platform
Industry MedicalNursingServices
Advertisement